Logo image of ONC

BEIGENE LTD-ADR (ONC) Stock Price, Quote, News and Overview

NASDAQ:ONC - Nasdaq - US07725L1026 - ADR - Currency: USD

230.98  +2.84 (+1.24%)

After market: 230.98 0 (0%)

ONC Quote, Performance and Key Statistics

BEIGENE LTD-ADR

NASDAQ:ONC (4/17/2025, 8:00:02 PM)

After market: 230.98 0 (0%)

230.98

+2.84 (+1.24%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap24.88B
Shares107.72M
Float7.99M
Yearly Dividend0.18
Dividend YieldN/A
PEN/A
Fwd PE382.11
Earnings (Next)05-01 2025-05-01
IPO02-03 2016-02-03


ONC short term performance overview.The bars show the price performance of ONC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

ONC long term performance overview.The bars show the price performance of ONC in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of ONC is 230.98 USD. In the past month the price decreased by -12.04%.

BEIGENE LTD-ADR / ONC Daily stock chart

ONC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.23B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B
INSM INSMED INC N/A 13.21B

About ONC

Company Profile

ONC logo image Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Company Info

BEIGENE LTD-ADR

c/o Mourant Governance Services (Cayman), 94 Solaris Avenue, Camana Bay

George Town BEIJING KY

Employees: 10473

Company Website: https://www.beigene.com/

Investor Relations: https://ir.beigene.com

Phone: 13459494123

BEIGENE LTD-ADR / ONC FAQ

What is the stock price of BEIGENE LTD-ADR today?

The current stock price of ONC is 230.98 USD. The price increased by 1.24% in the last trading session.


What is the ticker symbol for BEIGENE LTD-ADR stock?

The exchange symbol of BEIGENE LTD-ADR is ONC and it is listed on the Nasdaq exchange.


On which exchange is ONC stock listed?

ONC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BEIGENE LTD-ADR stock?

12 analysts have analysed ONC and the average price target is 281.37 USD. This implies a price increase of 21.82% is expected in the next year compared to the current price of 230.98. Check the BEIGENE LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BEIGENE LTD-ADR worth?

BEIGENE LTD-ADR (ONC) has a market capitalization of 24.88B USD. This makes ONC a Large Cap stock.


How many employees does BEIGENE LTD-ADR have?

BEIGENE LTD-ADR (ONC) currently has 10473 employees.


What are the support and resistance levels for BEIGENE LTD-ADR (ONC) stock?

BEIGENE LTD-ADR (ONC) has a support level at 230.74 and a resistance level at 242.76. Check the full technical report for a detailed analysis of ONC support and resistance levels.


Is BEIGENE LTD-ADR (ONC) expected to grow?

The Revenue of BEIGENE LTD-ADR (ONC) is expected to grow by 35.78% in the next year. Check the estimates tab for more information on the ONC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BEIGENE LTD-ADR (ONC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BEIGENE LTD-ADR (ONC) stock pay dividends?

ONC does not pay a dividend.


When does BEIGENE LTD-ADR (ONC) report earnings?

BEIGENE LTD-ADR (ONC) will report earnings on 2025-05-01.


What is the Price/Earnings (PE) ratio of BEIGENE LTD-ADR (ONC)?

BEIGENE LTD-ADR (ONC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.33).


What is the Short Interest ratio of BEIGENE LTD-ADR (ONC) stock?

The outstanding short interest for BEIGENE LTD-ADR (ONC) is 31.58% of its float. Check the ownership tab for more information on the ONC short interest.


ONC Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ONC.


Chartmill TA Rating
Chartmill Setup Rating

ONC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ONC. ONC may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ONC Financial Highlights

Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of -6.33. The EPS increased by 21.52% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -15.97%
ROE -26.99%
Debt/Equity 0.31
Chartmill High Growth Momentum
EPS Q2Q%1260.99%
Sales Q2Q%73.88%
EPS 1Y (TTM)21.52%
Revenue 1Y (TTM)N/A

ONC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ONC. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 109.55% and a revenue growth 35.78% for ONC


Ownership
Inst Owners26.4%
Ins OwnersN/A
Short Float %31.58%
Short Ratio3.54
Analysts
Analysts81.67
Price Target281.37 (21.82%)
EPS Next Y109.55%
Revenue Next Year35.78%